AIDS

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

Retrieved on: 
fredag, mars 15, 2024
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, ARV, GSK, HIV, COVID-19, AHF, Caribbean region of Colombia, Letter, AIDS Healthcare Foundation, Face, Biosimilar, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.

Key Points: 
  • AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.
  • In February, AHF and the Medical Research Foundation of Trinidad & Tobago sent a letter to GSK CEO Dame Emma Walmsley, which in part stated, “We urge you to address the lack of access to the antiretroviral drug Tivicay in Trinidad due to its high cost by lowering its price in line with biosimilar generics available in the Caribbean Region – or by committing not to threaten legal action against the purchase of a generic version of Tivicay.”
    To date, GSK has yet to respond to the letter.
  • Currently, Tivicay is under patent protection in Trinidad and Tobago, and GSK has threatened legal action if the country decides to import affordable generic ARVs.
  • “As a small island nation, Trinidad and Tobago is still recovering from the economic and social consequences of COVID-19 – paying 25 times more to provide lifelong HIV treatment for its people is untenable,” said AHF President Michael Weinstein.

AHF Thanks Matsui for Fighting Big PhRMA

Retrieved on: 
tisdag, mars 12, 2024
FDA, Men, Health, Family, Consumer, Congressional News, Views, Healthcare Reform, Public Policy, Government, Pharmaceutical, General Health, Health Insurance, Women, Other Policy Issues, Patient, AHF, AIDS, Congress, AIDS Healthcare Foundation, Prescription

AIDS Healthcare Foundation (AHF) applauds Representative Doris Matsui (D-CA) for her willingness to take on drug companies for their illegal contract pharmacy restrictions.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds Representative Doris Matsui (D-CA) for her willingness to take on drug companies for their illegal contract pharmacy restrictions.
  • As a 340B provider, AHF understands how contract pharmacy restrictions not only deny nonprofits vital savings but also interfere with their successful models of care.
  • “Drug companies have done everything possible to reduce the number of prescriptions available at 340B prices,” said Laura Boudreau, AHF Chief of Operations.
  • AHF is proud to support this bill.”
    As 340B finds itself in the crosshairs of drug makers bent on the program’s destruction, the 340B PATIENTS Act will provide the necessary pushback.

Protesters Keep Heat on Greedy Gilead over Price Gouging

Retrieved on: 
onsdag, mars 13, 2024
Men, General Health, Pharmaceutical, Consumer, State, Local, Infectious Diseases, Public Policy, Health Insurance, Women, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, AHF, Multimedia, Pharmacy, Pharmaceutical industry

HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.

Key Points: 
  • HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.
  • Protesters will gather Wednesday in front of the Loews Miami Beach Hotel where executives from Gilead will be presenting at the Barclays Annual Global Health Conference.
  • View the full release here: https://www.businesswire.com/news/home/20240312694416/en/
    The group hosted a similar protest rally targeting Gilead at the Fontainebleau Miami Beach Hotel Tuesday while company executives presented during the Leerink Partners Biopharma Conference.
  • HIV/AIDS activists are also specifically targeting Gilead CEO Daniel O’Day over his February appointment as board chair for PhRMA (Pharmaceutical Research and Manufacturers of America), the cutthroat trade group representing companies in the pharmaceutical industry in the United States.

AIDS Activists Protest CAA’s ‘Kill AHF’ Initiative, per AHF

Retrieved on: 
tisdag, mars 12, 2024
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, State, Local, Social Activism, Communications, Other Consumer, Philanthropy, Advocacy Group Opinion, Elections, Campaigns, Public Policy, Government, Foundation, AIDS, Consumer, Health, CAA, Patient, AHF, AIDS Healthcare Foundation, Justice, Landlord, Property management

AIDS activists affiliated with AHF will protest the California Apartment Association (CAA) outside its headquarters in Sacramento Wednesday as the anti-renter, corporate landlord front group attempts to put a proposition on the November 2024 ballot seeking to strip AIDS Healthcare Foundation (AHF) of its nonprofit status because of its advocacy for rent control.

Key Points: 
  • AIDS activists affiliated with AHF will protest the California Apartment Association (CAA) outside its headquarters in Sacramento Wednesday as the anti-renter, corporate landlord front group attempts to put a proposition on the November 2024 ballot seeking to strip AIDS Healthcare Foundation (AHF) of its nonprofit status because of its advocacy for rent control.
  • CAA has been gathering signatures for an anti-tenant, anti-patient ballot initiative deceptively titled ‘Protect Patients Now’ and has been doing so by lying to voters and taxpayers about how AHF makes its money.
  • AHF is the world’s largest HIV/AIDS healthcare organization and currently has 1.9 million patients in care.
  • CAA is aiming to strip AHF of its nonprofit status and kneecap its life-saving work around the globe over the fight for rent control in California.

Decolonizing Global Health a Must, says Pandemic Panel

Retrieved on: 
tisdag, mars 12, 2024
Public Policy, Government, AIDS, Health, COVID-19, Healthcare Reform, Infectious Diseases, Advocacy Group Opinion, AIDS Healthcare Foundation, Public health, University, Executive, Global health, Public, School of Public Health, WHO, AHF, Pandemic, School, Pharmaceutical industry

On March 8, during the CUGH 2024 conference , the AHF Global Public Health Institute and the University of California, Berkeley, School of Public Health convened a panel titled "Decolonizing Global Health Financing: Charting an Equitable Path Forward."

Key Points: 
  • On March 8, during the CUGH 2024 conference , the AHF Global Public Health Institute and the University of California, Berkeley, School of Public Health convened a panel titled "Decolonizing Global Health Financing: Charting an Equitable Path Forward."
  • This focused session shed light on redefining global health funding mechanisms to support pandemic prevention, preparedness, and response and reconstructing global health financing through equitable and sustainable partnerships.
  • Decolonizing global health is critical to addressing global health emergencies.
  • Regions should have the power to declare their own public health emergencies to mobilize international resources to respond to them effectively.”
    As countries negotiate to reshape the existing global health security architecture , it is vital that they adequately address decolonizing global health financing as a critical imperative.

AHF Keeps Pressure on ‘Greedy Gilead’ Over Price Gouging

Retrieved on: 
måndag, mars 11, 2024
Pharmaceutical, Philanthropy, Infectious Diseases, Healthcare Reform, Social Activism, Public Policy, Advocacy Group Opinion, Foundation, Communications, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, City, AHF, Pharmacy, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.

Key Points: 
  • AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.
  • AHF’s sustained protests against the drug maker continue as Gilead faces legal action over its keeping safer HIV medications off the market to maximize profits.
  • “It is so sadly apropos that Gilead CEO Daniel O’Day — the poster child for PhRMA greed — also now sits atop PhRMA, the undisputed fortress of greed,” said Michael Weinstein, AHF president and cofounder.
  • Since 2021, AHF has been taking on Gilead and CEO Daniel O’Day, holding more than two dozen protests in multiple cities, including Washington, DC, Miami, Boston, and Foster City, CA at Gilead’s corporate headquarters.

LOBOS 1707 TEQUILA PARTNERS WITH (RED) TO LAUNCH A LIMITED-EDITION REPOSADO BOTTLE TO SUPPORT LIFE-SAVING PROGRAMS THAT FIGHT AIDS

Retrieved on: 
tisdag, april 2, 2024
AIDS, Partnership, RED, Ageing, Global health, Sherry, Mark R. Dybul, CCO, LOBOS, Wine, LeBron James, Solera, Tequila, PX

NEW YORK, April 2, 2024 /PRNewswire/ -- Today, Lobos 1707 Tequila & Mezcal, the ultra-premium agave spirit brand, announces the launch of their (LOBOS 1707)RED Limited-Edition Reposado Tequila in partnership with (RED).

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- Today, Lobos 1707 Tequila & Mezcal, the ultra-premium agave spirit brand, announces the launch of their (LOBOS 1707)RED Limited-Edition Reposado Tequila in partnership with (RED).
  • Through the partnership, Lobos 1707 has committed to contribute $100,000 to the Global Fund to help strengthen global healthcare systems and fund life-saving programs in vulnerable communities.
  • Lobos 1707 Tequila & Mezcal was established as an independent spirits producer in 2020 by Founder and Chief Creative Officer, Diego Osorio, with investor, legendary athlete, and cultural icon LeBron James.
  • Lobos 1707's award-winning Reposado has been developed into a Limited-Edition (RED)-themed bottle, presenting its same ultra-premium bold liquid tied to this bolder mission to end AIDS.

The Inner Circle acknowledges Sharon E. Oster, MD, as a Pinnacle Life Member

Retrieved on: 
måndag, mars 11, 2024
Internal medicine, Phi Beta Kappa, AIDS, ASM, Patient, University, MD, Medical Center, Infection, Society, Love, ID, Inner circle, Pharmaceutical industry

BOISE, Idaho, March 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases.

Key Points: 
  • BOISE, Idaho, March 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases.
  • She followed this accomplishment at East Virginia Medical School where she completed a medical degree in 1980.
  • Recognized as the Resident of the Year award, the doctor completed her residency at the Veterans Administration (VA) Medical Center.
  • Considered a leader in her field, Dr. Oster is considered an expert in internal medicine and infectious diseases.

DIFFA'S STAR-STUDDED 40TH ANNIVERSARY GALA TICKETS ON SALE NOW

Retrieved on: 
onsdag, mars 6, 2024
Herman Miller, LGBTQ, Lighthouse, PRIDE, HOK, AIDS, Friends, Chelsea Piers, David Rockwell, FIT, Heel, Hope, SVA, Homelessness, Human, Hetrick-Martin Institute, Fashion, Gala, Table, Callen-Lorde Community Health Center, Council, Organization, Creativity, NYSID, SAGE, Steelcase, Housing Works, CFDA, Face, Student, Nightclub

New York, NY, March 06, 2024 (GLOBE NEWSWIRE) -- DIFFA is excited to announce its highly anticipated 40th Anniversary Gala on Thursday, March 28th at the Lighthouse at Chelsea Piers.

Key Points: 
  • New York, NY, March 06, 2024 (GLOBE NEWSWIRE) -- DIFFA is excited to announce its highly anticipated 40th Anniversary Gala on Thursday, March 28th at the Lighthouse at Chelsea Piers.
  • The Gala will commemorate a remarkable legacy—forty years of impactful DIFFA initiatives—and raise critical funds to further support these vital causes.
  • DIFFA is deeply grateful to Benjamin Moore, presenting sponsor of the 40th Anniversary Gala, as well as gold sponsors Empire Office with Steelcase, EvensonBest, HOK, MillerKnoll, Rockwell Group, and Shaw Contract.
  • The DIFFA gala is just one in several 40th anniversary fundraising events.

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Retrieved on: 
tisdag, mars 5, 2024
Infection, Fungal infection, CROI, NIH, AIDS, Vaccine Research Center, ACTG, Conference, Antibody, Safety, OPKO Health, Therapy, Pharmacokinetics, AIDS Clinical Trials Group, Modex, Trial of the century, HIV, HIV/AIDS, Immune system, Vaccine

WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.

Key Points: 
  • These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
  • The study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.
  • The antibody was safe and well-tolerated at all dose levels and via both intravenous and subcutaneous administration.
  • These clinical data on an HIV multispecific antibody inform the future advancement of such antibodies for the prevention and treatment of HIV and provide strong rationale for the development of current and future antibody products.